



News Release

Source: Patheon Inc.
Website: www.patheon.com

Patheon Signs Agreement with Swiftwater Group to Expand Regulatory Consulting Services

RESEARCH TRIANGLE PARK, North Carolina, (March 30, 2009) – Patheon Inc. (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to announce that it has entered into an alliance with Swiftwater Group, LLC to provide regulatory advisory services to support Patheon client's drug development programs.

Wes Wheeler, Chief Executive Officer and President of Patheon Inc. stated, "This new partnership allows Patheon to further expand its services portfolio. We have found that many of our clients benefit from strategic and tactical assistance with their NDA filings, 505(b) 2 filings, bioequivalence requirements, technical transfers and pediatric line extension strategies. We can now offer a complete service to our clients."

Swiftwater Group can assist Patheon clients as they navigate through the regulatory process, by providing expertise in regulatory strategy for CMC, non-clinical, and clinical development and by assisting clients to prepare and manage their regulatory submissions. Thomas Fritz, Managing Partner of Swiftwater Group, LLC noted: "With the combined resources of our two companies, we are uniquely positioned to offer Integrated Drug Development services that span the full development spectrum from pre-clinical to regulatory approval, at the same time ensuring tight coordination of product manufacture, nonclinical program development and execution, clinical study design and execution, and regulatory documentation."

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate

early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated network strives to ensure that customer products can be launched with confidence globally.

ABOUT SWIFTWATER

Swiftwater Group (www.swiftwater.com) is a Drug Development Management Consulting firm that offers services to pharmaceutical companies world-wide. For more than ten years, Swiftwater Group has helped companies create the most effective and efficient strategies for gaining approval from US and ex-US regulatory agencies. Because Swiftwater Group is not affiliated with any specific CRO, it is able to provide unbiased recommendations to its clients that ensure cost-effective study design and implementation.

Swiftwater Group offers services in regulatory strategy development and execution, non-clinical and clinical program design and management, writing of all regulatory documents, clinical trial monitoring, and Quality Assurance operations. Relying on the extensive experience of its principals, the company helps clients manage their global development programs, ensuring optimum efficiency of financial and human resources, with the goal of maximizing the value of the pharmaceutical product.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts:

Mr. Wes Wheeler
President & Chief Executive Officer
Tel: (919) 226-3201
Email: wes.wheeler@patheon.com

Ms. Jean Treadwell
Investor Relations
Tel: (905) 816-8344
Email: jean.treadwell@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3204
Email: eric.evans@patheon.com